Events

Bio Integrates 202​1:

Join our CFO Patrick Driscoll as he joins a panel for a session entitled – “Should I stay or should I go?”. Brexit and the imminent funding gap has led to companies looking to locate elsewhere. We hear from countries/regions trying to attract Life Science companies.

Bio International 2021

BIO Digital is the world’s largest virtual biotech partnering and education event, convening thousands of global biotech leaders and innovators.

More information coming soon…

An Introduction to Organ-On-a-Chip

The Future of Pre-clinical Drug Research. Join Vaish Manoharan, Account Manager at CN Bio.

The Scars of Fat

The Transability of 3D NASH Microtissues To Model Human/murine NASH. Join Dr Michele Vacca, Clinical Research Associate Institute of Metabolic Science, TVP Lab at University of Cambridge

Go with the Flow

Application of Microfluidic 3D Liver Chip Models To Genotoxicity Testing. Join Dr Renato Cardoso, Scientific Director of Genetic Toxicology and Dr Thalita Zanoni, Senior Research Scientist at Charles River Laboratories (Montreal – Canada)

A Regulators Viewpoint

Establishing Strategies To Evaluate Microphysiological Systems for Drug Development. Join Dr Alexandre Ribeiro, Staff Fellow (Biological Scientist) at the FDA.

The Rhythm of Life

Using Microfluidics To Mimic Blood Flow in Single- and Multi-Organ-on-a-Chip Models. Join Dr Graham Broder, Associate Director Engineering and Alysha Bray, Scientist at CN Bio.

Testing on Humans

How to Predict Hepatotoxicity and Drug Clearance Ahead of Clinical Trials Using Liver-on-a-Chip. Join Dr Tomasz Kostrzewski, Director of Biology at CN Bio

A Microphysiological Model of Metastatic Progression

Using systems to model metastatic progression. Join Dr Amanda Clark, Research Assistant Professor at University of Pittsburgh.

Engineering Mucosal Barriers

From Organoids to Organs-on-Chips with Professor Linda Griffith, S.E.T.I. Professor of Biological and Mechanical Engineering Research
Director of the Center for Gynepathology Research at MIT

Towards a Body-on-a-Chip:

The Value of Multi-Organ MPS for Human-Relevant Drug Assessment. Join Dr Tomasz Kostrzewski, Director of Biology at CN Bio for a brand new webinar exploring how single and multi-organ MPS can be incorporated into your drug discovery and development workflows to increase translation of pre-clinical assays.

Pathologically Scarred by Fibrosis:

How To Model and Quantify Human NASH in a Microphysiological System. Non-alcoholic steatohepatitis (NASH) is a widespread disease affecting up to ~12% of the US population – characterized by lipid accumulation in hepatocytes, infiltration of immune cells and fibrosis of the liver. Replicating liver fibrosis is a key element in any in vitro NASH model, however, it is normally poorly assessed, unquantifiable and has a limited dynamic range.